Literature DB >> 22282852

Ketanserin and mianserin treatment reverses hyperactivity in neonatally dopamine-lesioned rats.

J Luthman1, A Fredriksson, A Plaznik, T Archer.   

Abstract

Selective brain dopamine (DA) depletions in rats, induced by neonatal intracisternal administration of 6-hydroxydopamine (6-OHDA; 75 μg), caused spontaneous hyperactivity at the adult stage as measured using determinations of locomotion, rearing and total activity. Treatment with ketanserin (0.5 or 1.0 mg/kg, s.c.) reversed the hyperactivity in 6-OHDA-treated animals during a 90-min period following injection, although only the low dose of ketanserin reduced rearings. In control animals ketanserin treatment did not affect the locomotion or total activity counts, while the high dose of ketanserin increased rearings. Following treatment with mianserin (0.5 or 1.0 mg/kg, s.c.), a similar effect was seen; however, it was longer-lasting and mianserin treatment increased activity in controls. Regional analysis of monoamine levels demonstrated a marked reduction of basal forebrain DA levels, while in striatum an increase in serotonin (5-HT) concentration was seen following the 6-OHDA treatment. The results indicate that drugs with a high affinity to 5-HT(2) binding sites can influence the hyperactivity seen in neonatally DA-lesioned rats. This effect might be related to inhibition of 5-HT pathways directly involved in regulation of motor activity or due to alterations in the interaction between the DA and 5-HT systems as a consequence of the early DA lesion.

Entities:  

Year:  1991        PMID: 22282852     DOI: 10.1177/026988119100500437

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  8 in total

1.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

2.  Interaction between the endocannabinoid and serotonergic system in the exhibition of head twitch response in four mouse strains.

Authors:  Chiara Ceci; Martina Proietti Onori; Simone Macrì; Giovanni Laviola
Journal:  Neurotox Res       Date:  2014-12-17       Impact factor: 3.911

3.  Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons.

Authors:  N Laprade; F Radja; T A Reader; J J Soghomonian
Journal:  J Neurosci       Date:  1996-06-01       Impact factor: 6.167

4.  Functional deficits following neonatal dopamine depletion and isolation housing: circular water maze acquisition under pre-exposure conditions and motor activity.

Authors:  Trevor Archer; Tomás Palomo; Anders Fredriksson
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

5.  Behavioural supersensitivity following neonatal 6-hydroxydopamine: attenuation by MK-801.

Authors:  T Archer; Anders Fredriksson
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

6.  Neonatal 6-hydroxydopamine-induced hypo/hyperactivity: blockade by dopamine reuptake inhibitors and effect of acute D-amphetamine.

Authors:  Trevor Archer; Tomas Palomo; Anders Fredriksson
Journal:  Neurotox Res       Date:  2002-05       Impact factor: 3.911

7.  Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment.

Authors:  Trevor Archer; Tomas Palomo; Robert McArthur; Anders Fredriksson
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

Review 8.  Brain sites of movement disorder: genetic and environmental agents in neurodevelopmental perturbations.

Authors:  T Palomo; R J Beninger; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.